| Home | E-Submission | Sitemap | Contact Us |  
logo
The Korean Journal of Medicine 2009;77(2): 152-156.
내성 결핵균의 실태 및 치료
임 재 준
Current status of drug-resistant tuberculosis and its treatment
Jae-Joon Yim
ABSTRACT
Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients. (Korean J Med 77:152-156, 2009)
Keywords: Tuberculosis; Drug resistance; Treatment
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail
Share:      
METRICS
794
View
7
Download
Current Status of Medical Disputes, Prospects and Cautions  2019 June;94(3)
Diagnosis and Treatment of Multidrug-Resistant Tuberculosis  2015 May;88(5)
Social Burden of Drug Allergy and its Prevention  2014 December;87(6)
Current Status of Primary Glomerulonephritis  2013 January;84(1)
Current Status of Tuberculosis in Korea  2011 March;82(3)
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community